Larkspur Biosciences
Larkspur Biosciences is dedicated to developing transformative small molecule medicines targeting cancer cell fitness genes to destroy tumors more effectively. The company focuses on overcoming limitations of current therapies by targeting enzymes that control cancer cell state and fitness, making cancer cells more susceptible to intrinsic and immune-mediated killing. With a proven track record in drug discovery and development, Larkspur aims to solve hard problems and deliver new medicines to cancer patients with significant unmet needs. Their approach involves innovative strategies to previously intractable targets, leveraging a proprietary platform called LarkX that uses tumor genetics and immune phenotypes from patient-derived data to fuel their pipeline and address multiple cancer types.
Industries
Nr. of Employees
small (1-50)
Larkspur Biosciences
Watertown, Massachusetts, United States, North America
Products
PIP4K2C-targeted protein degrader (first-in-class program)
A first-in-class small-molecule protein degrader directed against PIP4K2C designed to reduce cancer cell fitness and sensitize tumors to intrinsic and immune-mediated killing; demonstrated preclinical activity in colorectal cancer models and patient-derived samples.
Pin1-targeting small-molecule program
A small-molecule development program targeting Pin1 to reprogram fibroblasts in the tumor microenvironment and drive a pro-immune phenotype.
B cell checkpoint–targeting program (TIM-1 target)
A program developing modulators of a B cell–linked receptor involved in antigen presentation and tertiary lymphoid structure formation to prime interferon-gamma–secreting T cell responses.
Machine-learning gene-signature discovery platform
Computational platform that applies machine learning to gene-signature data to identify pathways and targets associated with cancer cell–intrinsic adaptations and immune evasion for target selection.
PIP4K2C-targeted protein degrader (first-in-class program)
A first-in-class small-molecule protein degrader directed against PIP4K2C designed to reduce cancer cell fitness and sensitize tumors to intrinsic and immune-mediated killing; demonstrated preclinical activity in colorectal cancer models and patient-derived samples.
Pin1-targeting small-molecule program
A small-molecule development program targeting Pin1 to reprogram fibroblasts in the tumor microenvironment and drive a pro-immune phenotype.
B cell checkpoint–targeting program (TIM-1 target)
A program developing modulators of a B cell–linked receptor involved in antigen presentation and tertiary lymphoid structure formation to prime interferon-gamma–secreting T cell responses.
Machine-learning gene-signature discovery platform
Computational platform that applies machine learning to gene-signature data to identify pathways and targets associated with cancer cell–intrinsic adaptations and immune evasion for target selection.
Services
Collaborative research and development partnerships
Joint research and co-development arrangements to advance therapeutic programs and target-specific projects.
Collaborative research and development partnerships
Joint research and co-development arrangements to advance therapeutic programs and target-specific projects.
Expertise Areas
- Small-molecule drug discovery
- Targeted protein degradation
- Tumor microenvironment modulation
- Biomarker-driven clinical development
Key Technologies
- Small-molecule medicinal chemistry
- Targeted protein degradation
- Machine-learning gene-signature analysis
- Biomarker discovery and analytics